ACROBiosystems has successfully launched its Claudin family proteins, including Claudin 18.2, Claudin 18.1, Claudin 6, and Claudin 9, using its FLAG technology, a series of multi-pass transmembrane protein development platforms. Claudins are a family of proteins that have been recently identified to play a role in oncogenesis and can assist in cancer prognosis. Generally, these full-length multi-pass transmembrane target antigens are difficult to prepare while maintaining their native conformation. However, through our technology, we offer full-length Claudin family proteins with high bioactivity and batch-to-batch consistency that is verified through ELISA, SPR, BLI, FACS, and other methods, to support your innovative drug research and development.
|Platform||Molecule||Cat. No.||Product Description|
>> Multi-pass Transmembrane Proteins Platform
>> [Inspiring Target] Breakthroughs of targeting Claudin 6 in mAb, bsAb, ADC, CAR-T cell therapy
This web search service is supported by Google Inc.